Reversal of vasohibin-driven negative feedback loop of vascular endothelial growth factor/angiogenesis axis promises a novel antifibrotic therapeutic strategy for liver diseases

Hepatology

Volumn 60, Issue 2, 2014, Pages 458-460

  Chatterjee, Suvro ^a,b  

^a AU KBC Research Centre   (India)

^b ANNA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 8; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASOHIBIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; DOWN REGULATION; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER REGENERATION; NEGATIVE FEEDBACK; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCAR FORMATION; STELLATE CELL;

ANIMALS; CELL CYCLE PROTEINS; HUMANS; LIVER CIRRHOSIS; MALE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904757023     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27061     Document Type: Article

References (19)

1. Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, et al. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene 2013;32:1724-1734.
2. Wang Q, Tian X, Zhang C, Wang Q. Upregulation of vasohibin-1 expression withangiogenesis and poor prognosis of hepatocellular carcinoma after curativesurgery. Med Oncol 2012;29:2727-2736.
3. Nygård IE, Mortensen KE, Hedegaard J, Conley LN, Kalstad T, Bendixen C, Revhaug A. The genetic regulation of the terminating phase of liver regeneration. Comp Hepatol 2012;11:3.
4. Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, et al. Disruption of negative feedback loop between vasohibin-1 and VEGF decreases portal pressure, angiogenesis and fibrosis in cirrhotic rats. Hepatology 2014;60:633-647.
5. Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004;114:898-907.
6. Saito D, Maeshima Y, Nasu T, Yamasaki H, Tanabe K, Sugiyama H, et al. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis. Am J Physiol Renal Physiol 2011;300:F873-F886.
7. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010;53:976-980.
8. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-1562.
9. Dufour JF, Clavien PA, eds. Signaling Pathways in Liver Diseases. Berlin: Springer-Verlag; 2010:41-68.
10. Shackel NA, McGuinness P, Abbott C, Gorrell M, McCaughan G. Identication of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 2001;49:567-576.
11. U.S. Food and Drug Administration. FDA Commissioner announces Avastin decision-drug not shown to be safe and effective in breast cancer patients. 2011. Available at: www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf. Accessed February 21, 2014.
12. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;31:146-162.
13. Piguet AC, Majumder S, Balaguru UM, Manjunathan R, Saran U, Chatterjee S, Dufour JF. Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities. Clin Sci (Lond) 2013 Nov 28. [Epub ahead of print].
14. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007;46:1919-1926.
15. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-1327.
16. Huang Y, Feng H, Kan T, Huang B, Zhang M, Li Y, et al. Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells. PLoS One 2013;8:e73492.
17. Muley A, Majumder S, Kolluru GK, Parkinson S, Viola H, Hool L, et al. Secreted frizzled-related protein 4: an angiogenesis inhibitor. Am J Pathol 2010;176:1505-1516.
18. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012;55:622-633.
19. Kozako T, Matsumoto N, Kuramoto Y, Sakata A, Motonagare R, Aikawa A, et al. Vasohibin induces prolyl hydroxylase-mediated degradation of hypoxia-inducible factor-1α in human umbilical vein endothelial cells. FEBS Lett 2012;586:1067-1072.